PL1622639T3 - Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu - Google Patents

Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu

Info

Publication number
PL1622639T3
PL1622639T3 PL04730516T PL04730516T PL1622639T3 PL 1622639 T3 PL1622639 T3 PL 1622639T3 PL 04730516 T PL04730516 T PL 04730516T PL 04730516 T PL04730516 T PL 04730516T PL 1622639 T3 PL1622639 T3 PL 1622639T3
Authority
PL
Poland
Prior art keywords
plasminogen
intravenous injection
treating cerebral
cerebral stroke
neurotoxic
Prior art date
Application number
PL04730516T
Other languages
English (en)
Inventor
Mariola Söhngen
Wolfgang Söhngen
Wolf-Dieter Schleuning
Robert Medcalf
Original Assignee
Lundbeck H As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/004729 external-priority patent/WO2004096267A1/de
Application filed by Lundbeck H As filed Critical Lundbeck H As
Publication of PL1622639T3 publication Critical patent/PL1622639T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04730516T 2003-05-02 2004-04-30 Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu PL1622639T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPPCT/EP03/04608 2003-05-02
PCT/EP2003/004729 WO2004096267A1 (de) 2003-05-02 2003-05-06 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
EP04730516A EP1622639B1 (de) 2003-05-02 2004-04-30 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
PCT/EP2004/004626 WO2004096268A2 (de) 2003-05-02 2004-04-30 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall

Publications (1)

Publication Number Publication Date
PL1622639T3 true PL1622639T3 (pl) 2013-06-28

Family

ID=35610451

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04730516T PL1622639T3 (pl) 2003-05-02 2004-04-30 Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu

Country Status (10)

Country Link
EP (1) EP1622639B1 (pl)
JP (1) JP2006525270A (pl)
KR (1) KR101212631B1 (pl)
BR (1) BRPI0409865A (pl)
CA (1) CA2524573A1 (pl)
HR (1) HRP20050903B1 (pl)
NO (1) NO337485B1 (pl)
NZ (1) NZ543367A (pl)
PL (1) PL1622639T3 (pl)
WO (1) WO2004096268A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
WO2008022801A1 (en) * 2006-08-25 2008-02-28 Paion Deutschland Gmbh Method for the manufacture of a medicament for treating hemorrhagic stroke
EP1897554A1 (en) * 2006-08-25 2008-03-12 PAION Deutschland GmbH Method for the manufacture of a medicament for treating hemorrhagic stroke
JP2010524855A (ja) 2007-04-13 2010-07-22 ディフュージョン・ファーマシューティカルズ・エルエルシー 末梢血管疾患の前処置としての、及びその処置における双極性トランスカロテノイドの使用
ES2847293T3 (es) 2009-06-10 2021-08-02 Nono Inc Regímenes de tratamiento para el tratamiento de enfermedades neurológicas
AU2010263245A1 (en) 2009-06-22 2012-01-19 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
JP5823671B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 免疫製剤を含む脳梗塞治療用医薬品組成物
JP5823672B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
DK3427748T3 (da) * 2011-06-24 2022-04-19 Nono Inc Kombinationsterapi mod iskæmi
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
KR102489034B1 (ko) 2016-03-24 2023-01-13 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE69054B1 (en) * 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Also Published As

Publication number Publication date
BRPI0409865A (pt) 2006-05-16
NO20055692L (no) 2006-01-30
KR101212631B1 (ko) 2012-12-14
WO2004096268A2 (de) 2004-11-11
KR20060020616A (ko) 2006-03-06
HRP20050903A2 (en) 2006-08-31
WO2004096268A3 (de) 2005-04-21
NO337485B1 (no) 2016-04-25
NZ543367A (en) 2010-06-25
EP1622639B1 (de) 2013-01-16
EP1622639A2 (de) 2006-02-08
NO20055692D0 (no) 2005-12-01
CA2524573A1 (en) 2004-11-11
HRP20050903B1 (hr) 2013-11-22
JP2006525270A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
NO20055692D0 (no) Intravenos injeksjon av ikkeneurotoksiske plasminogenaktivatorer til behandling av cerebralt slag
EG24106A (en) Machine for injecting liquids
HK1070386A1 (en) Methods for production of recombinant urokinase
EP1859914A4 (en) METHOD FOR ADJUSTING THE CASTING CONDITIONS AND METHOD FOR CONTROLLING AN INJECTION MOLDING MACHINE
HK1091410A1 (en) Tlr7 ligands for the treatment of hepatitis c
IL173439A0 (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
IL175014A0 (en) Method of administering therapeutic injections
PL372211A1 (pl) Tiazolilomoczniki w leczeniu raka
AU2003295537A8 (en) Methods of treating cerebral ischemia
HUP0402165A3 (en) Non-neurotoxic plasminogen activating factors for treating stroke
ZA200703704B (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
AU2002350660A1 (en) Non-neurotoxic plasminogen activating factors for treating stroke
SI1697383T1 (sl) Postopek za čiščenje takrolimusa
EP1626692A4 (en) COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS
HK1087064A1 (en) Injection-molding machine and method of controlling injection-molding machine
AU2003296705A8 (en) Method for controlling the production of injection molded parts
IL173953A0 (en) Plasminogen activators
EP1684783A4 (en) NEUROPROTECTIVE EFFECTS OF GLY-PRO-GLU AFTER INTRAVENOUS INFUSION
AU2003213596A8 (en) Intraspinal continuous infusion of midazolam hydrochloride for the treatment of pain
GB2419843B (en) Process control for gas-assisted injection molding applications
HK1103687A1 (en) Injection member of molding machine and molding method
IL156566A0 (en) Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis
TW569918U (en) Auxiliary jig for forming mold of needle injecting type label piece
GB2401573B (en) Needle assembly for gas-assisted injection moulding
GB0125597D0 (en) Controlling injection moulding processes